Use of atypical antipsychotics in autism

Autism Spectrum Disorders

Volumn , Issue , 2003, Pages 247-264

  Posey, David J ^a   McDougle, Christopher J ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22144443947     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and Practice of Psychopharmacotherapy. Philadelphia: Lippincott Williams & Wilkins, 2001.
2. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961; 58:315-320.
3. Anderson GM, Hoshino Y. Neurochemical studies of autism. In: Handbook of Autism and Pervasive Developmental Disorders. Cohen DJ, Hoshino Y, eds. New York: John Wiley & Sons, 1997:325-343.
4. McBride PA, Anderson GM, Hertzig ME, Snow ME, Thompson SM, Khait VD, Shapiro T, Cohen DJ. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1998; 37(7):767-776.
5. Hoshino Y, Tachibana JR, Watanabe M, Murata S, Yokoyama F, Kaneko M, Yashima Y, Kumoshiro H. Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction. Jpn J Psychiatry Neurol 1984; 26:937-945.
6. McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J, Cohen DJ, Mann JJ. Serotonergic responsivity in male young adults with autistic disorder: results of a pilot study. Arch Gen Psychiatry 1989; 46:213-221.
7. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drugfree adults with autistic disorder. Arch Gen Psychiatry 1996; 53:993-1000.
8. Hollander E, Novotny S, Allen A, Aronowitz B, Cartwright C, DeCaria C. The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 2000; 22(2): 163-167.
9. Geller E, Ritvo E, Freeman B, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 1982; 307:165-169.
10. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581-588.
11. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441-447.
12. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001-1008.
13. Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31(4):739-745.
14. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998; 18(1):62-66.
15. Posey DJ, Litwiller M, Koburn A, McDougle CJ. Paroxetine in autism. J Am Acad Child Adolesc Psychiatry 1999; 38(2):111-112.
16. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Rev Psychiatry 2000; 8(2):45-63.
17. Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res 1976; 19:70-83.
18. Campbell M, Anderson L, Meier M, Cohen I, Small A, Samit C, Sachar E. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry 1978; 17(4):640-655.
19. Gillberg C, Svennerholm L, Hamilton-Hellberg C. Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Disord 1983; 13:383-396.
20. Narayan M, Srinath S, Anderson GM, Meundi DB. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry 1993; 33:630-635.
21. Minderaa RB, Anderson GM, Volkmar F, Harcherik D, Akkerhuis CW, Cohen DJ. Neurochemical study of dopamine functioning in autistic and normal subjects. J Am Acad Child Adolesc Psychiatry 1989; 28:200-206.
22. Anderson L, Campbell M, Grega D, Perry R, Small A, Green W. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141:1195-1202.
23. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19:227-239.
24. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, Overall JE. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28:87-92.
25. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36:835-843.
26. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40.
27. Volkmar FR, Cohen DJ. Comorbid association of autism and schizophrenia. Am J Psychiatry 1991; 148:1705-1707.
28. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6:177-190.
29. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A doubleblind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55:633-641.
30. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996; 153:738.
31. Vanden Borre R, Vermote R, Buttiens M, Thiry P, Dierick G, Geutjens J, Sieben G, Heylen S. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1993; 87:167-171.
32. Purdon SE, Lit W, Labelle A, Jones DW. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994; 39:400-405.
33. McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH. Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 1995; 5(4):273-282.
34. Simeon JB, Carrey NJ, Wiggins DM, Milin RP, Hosenbocus SN. Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychopharmacol 1995; 5(1):69-79.
35. Demb HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities. J Child Adolesc Psychopharmacol 1996; 6(1): 79-80.
36. Hardan A, Johnson K, Johnson C, Hrecznyj B. Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35:1551-1556.
37. Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 1996; 32:721-729.
38. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33: 155-159.
39. Frischauf E. Drug therapy in autism. J Am Acad Child Adolesc Psychiatry 1997; 36(5):577.
40. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997; 27:313-323.
41. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label investigation. J Am Acad Child Adolesc Psychiatry 1997; 36(5):685-693.
42. Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and followup. J Child Adolesc Psychopharmacol 1997; 7:167-179.
43. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatry Ann 1997; 27:219-221.
44. Cohen SA, Ihrig K, Lott RS, Kerrick JM. Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord 1998; 28(3): 229-233.
45. Doan RJ. Risperidone for insomnia in PDDs. Can J Psychiatry 1998; 43(10):1050-1051.
46. Nicolson R, Awad G, Sloman L. An open label trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37:372-376.
47. Schwam JS, Klass E, Alonso C, Perry R. Risperidone and refusal to eat. J Am Acad Child Adolesc Psychiatry 1998; 37(6):572-573.
48. Dartnall NA, Holmes JP, Morgan SN, McDougle CJ. Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord 1999; 29(1):87-91.
49. Posey DJ, Walsh KH, Wilson GA, McDougle CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 1999; 9: 273-276.
50. Zuddas A, Di Martino A, Muglia P, Cianchetti C. Long-term risperidone for perva sive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000; 10(2):79-90.
51. Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997; 36:1166-1167.
52. Malek-Ahmadi P, Simonds JF. Olanzapine for autistic disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1998; 37:902.
53. Heimann SW. High-dose olanzapine in an adolescent. J Am Acad Child Adolesc Psychiatry 1999; 38(5):496-497.
54. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolscents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19:37-44.
55. Kemner C, van Engeland H, Tuynman-Qua H. An open-label study of olanzapine in children with PDD. Schizophr Res 2000; 41(1):194.
56. Martin A., Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9:99-107.
57. Guy W. ECDEU Assessment Manual for Psychopharmacology. Publication 76-338. Washington, DC: National Institute of Mental Health, U.S. Department of Health, Education and Welfare, 1976.
58. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar F, Votolato NA, Walson P. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: background and rationale for an initial controlled study of risperidone. Psychopharmacology 2000; 9(1):201-224.
59. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F. Assessment in multisite randomized clinical trials of patients with autistic disorder: the autism RUPP network. J Autism Dev Disord 2000; 30(2):99-111.
60. Bymaster FP, Calliguro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wang DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96.
61. Heuring RE, Peroutka SJ. Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 1987; 7:894-903.
62. Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987; 44(3):211-218.
63. Aman MG, Singh NN, Stewart AW, Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89:485-491.
64. Findling RL, McNamara NK, Gracious BL. Paediatric uses of atypical antipsychotics. Exp Opin Pharmacother 2000; 1(5):935-945.
65. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39(3):292-299.
66. McDougle CJ, Kem DL, Posey DJ. Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41(8):921-927.
67. Moller HJ, Pelzer E, Kissling W, Riehl T, Wernicke T. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry 1991; 24(6):185-189.
68. Feeney DJ, Klykylo W. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 1996; 35(11):1421-1422.
69. Campbell M. Risperidone-induced tardive dyskinesia in first-episode psychotic patients. J Clin Psychopharmacol 1999; 19(3):276-277.
70. Mandoki MW. Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 1995; 5(1):49-67.
71. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and convential antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8(3):151-159.
72. Fuller M, Simon M, Freedman L. Risperidone-associated hepatoxicity. J Clin Psychopharmacol 1996; 16:84-85.
73. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: risperidoneinduced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997; 36(5):701-705.
74. Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL. Risperidoneinduced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 1999; 9(2):93-98.
75. Ravin DS, Leverson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997; 31:867-869.
76. Edleman RJ. Risperidone side effects. J Am Acad Child Adolesc Psychiatry 1996; 35:4-5.
77. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41: 396-371.
78. Lane H-L, Chang W-H, Chou JC-W. Seizure during risperidone treatment in an elderly woman treated with concomitant medications. J Clin Psychiatry 1998; 59(2): 81-82.
79. Hudson RG, Cain MP. Risperidone associated hemorrhagic cystitis. J Urol 1998; 160(1):159.
80. Emborg C. Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskr Laeger 1999; 161(10):1424-1425.
81. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314-321.